Pharmaceutical giant Biogen and its Japanese partner Eisai announced a few weeks ago they were halting two phase three clinical trials of a drug that targets the buildup in the brain of beta-amyloid, one of two proteins that researchers believe contribute to the development of Alzheimer’s. The drug, called aducanumab, was the most promising candidate in a field that has been littered with failures. It was so promising that the company was running two phase three trials simultaneously, said neurologist Dr. Richard Isaacson, who directs the Alzheimer’s Prevention Clinic at Weill Cornell in New York.
On April 11, 2019, at our NJ Elder Care Symposium, we will have Jeff Borghoff, a participant in the Biogen clinical trial, as part of a panel discussing his experience. You can still register for the NJ Symposium on the link below.